The Mind's New Architects: Psychedelic Therapy Approvals and the Multi-Billion Dollar Infrastructure Build-Out
The mental health crisis has long been a silent, insidious drain on human potential and economic productivity. It costs the global economy an estimated $1 trillion annually in lost output. Now, with the imminent FDA approvals of MDMA and psilocybin for therapeutic use, we stand at the threshold of a profound transformation. This moment unlocks a potential market for psychedelic-assisted therapy that could reach $100 billion annually within the next decade. This isn't merely about new compounds; it's about constructing an entirely new therapeutic architecture, from specialized clinics and trained professionals to digital platforms and novel payment models, creating a monumental investment opportunity.
For decades, mental health treatment has largely operated within a familiar, if often insufficient, framework: daily pills and weekly talk therapy. This approach, while helpful for many, has left a vast chasm of unmet need. This is particularly true for conditions like treatment-resistant depression (TRD) and post-traumatic stress disorder (PTSD), which continue to devastate lives and economies. The sheer scale of this suffering is staggering.
Roughly 300 million people worldwide grapple with depression, and an estimated 13 million adults in the U.S. alone live with PTSD [1, 2]. These aren't just statistics; they represent a profound human cost. They also reveal an equally profound market failure.
Enter the psychedelics. Once relegated to the fringes of counter-culture and illicit use, compounds like MDMA and psilocybin are now emerging from rigorous clinical trials. Their data is so compelling it forces a re-evaluation of mental healthcare's very foundations. The U.S. Food and Drug Administration (FDA) has granted "Breakthrough Therapy Designation" to both MDMA for PTSD and psilocybin for TRD, a rare recognition. This designation is reserved for treatments that show substantial improvement over available therapies for serious conditions [3]. This isn't just bureaucratic shorthand; it's a fast-track pass, signaling that the FDA sees these compounds not as mere incremental improvements, but as genuine catalysts.
This isn't just about a new class of pharmaceuticals; it's about a complete re-architecting of how we approach mental healing. The therapy model itself is fundamentally different, requiring highly specialized, supervised sessions that integrate pharmacological effects with intensive psychological support. This unique delivery mechanism necessitates a vast, entirely new infrastructure. This includes purpose-built treatment centers designed for safety and efficacy, and a newly trained cadre of therapists capable of navigating these profound inner landscapes.
The market, currently nascent and largely pre-commercial, is poised for an explosive expansion. Projections for psychedelic-assisted therapies range from $10 billion to $100 billion annually, depending on the breadth of indications and accessibility post-approval [4]. This isn't just a niche market; it's a tectonic shift, promising not only improved patient outcomes but also unprecedented investment opportunities across a complex, multi-layered value chain.
The journey of psychedelics from illicit substances to legitimate medical tools has been a long, winding, and often controversial one. For decades, these compounds were effectively banished from scientific inquiry. Their therapeutic potential was overshadowed by political narratives and public fear. Yet, beneath the surface, a quiet revolution was brewing, fueled by dedicated researchers and philanthropists who saw beyond the stigma. Now, the dam has broken. The scientific community openly embraces the potential of these molecules to unlock new pathways to healing.
The current terrain is defined by the undeniable weight of clinical evidence. For MDMA-assisted therapy for PTSD, the data from MAPS Public Benefit Corporation (MAPS PBC) has been nothing short of transformative. Their Phase 3 trials, MAPP1 and MAPP2, demonstrated highly statistically significant and clinically meaningful reductions in PTSD symptoms. A substantial portion of participants no longer met the diagnostic criteria for PTSD after treatment [5]. This isn't just symptom management; it's often remission. The anticipated submission of a New Drug Application (NDA) to the FDA in late 2023 or early 2024 sets the stage for potential FDA approval by late 2024 or early 2025. This will be a landmark event, officially ushering in a new era of mental healthcare.
Similarly, psilocybin-assisted therapy for treatment-resistant depression (TRD) shows immense promise. COMPASS Pathways (CMPS), a publicly traded company, leads the charge with its proprietary psilocybin formulation, COMP360. Their Phase 2b trial, involving 233 participants, showed a significant reduction in depressive symptoms, paving the way for their ongoing Phase 3 program [6]. Top-line data from their first pivotal trial is expected in mid-2024, with subsequent approvals potentially following. The Usona Institute, a non-profit, also makes strides with psilocybin for major depressive disorder (MDD), with promising Phase 2 data and ongoing Phase 3 trials [7].
These approvals, once secured, will trigger a cascading series of developments across the healthcare ecosystem. The immediate impact will be the legitimization of these therapies. This opens doors for insurance coverage, professional training, and the establishment of dedicated treatment facilities. This isn't a simple pill-in-a-bottle scenario. The therapy itself is integral to the treatment, requiring multiple hours of guided sessions before, during, and after the psychedelic experience. This necessitates a robust, specialized infrastructure that simply does not exist at scale today.
Regulatory Approval → Insurance Coverage → Therapist Training → Clinic Build-Out → Widespread Patient Access → Multi-Billion Dollar Market.
The market size estimates are compelling. For MDMA-assisted therapy alone, annual revenues could range from $3 billion to $10 billion annually within five years of approval, addressing a significant portion of the PTSD population [4]. Psilocybin, with its broader applicability to TRD and potentially MDD, could command an even larger market, potentially $5 billion to $20 billion annually, given the larger patient population struggling with various forms of depression [4]. These figures underscore not just the therapeutic potential, but the immense economic opportunity for those positioned to build and operate this nascent industry. The terrain is shifting from a scientific curiosity to a full-fledged, investable sector.
To call MDMA and psilocybin "drugs" in the traditional sense risks missing the forest for the trees. They are, more accurately, catalysts for a therapeutic process, facilitators for profound psychological shifts that conventional pharmaceuticals often fail to achieve. The true "technology" here isn't just the molecule itself, but the meticulously designed therapeutic protocol that surrounds its administration. This is where the real innovation, and the real infrastructure build-out, lies.
Consider MDMA-assisted therapy for PTSD. The protocol developed by MAPS PBC is a carefully orchestrated sequence of preparatory sessions, supervised MDMA sessions, and integrative therapy sessions [8]. Patients typically undergo 3 preparatory sessions, followed by 3 full-day MDMA sessions (each lasting 6-8 hours), interspersed with 9 integration sessions over several weeks. During the MDMA sessions, patients lie on a couch with eye shades and headphones, listening to curated music, while two trained therapists provide non-directive support. The MDMA doesn't "cure" PTSD; it creates a temporary window of neurobiological plasticity and emotional openness, allowing patients to process traumatic memories with reduced fear and increased compassion. It’s like a temporary override of the brain's alarm system, enabling deep, reconstructive work.
Psilocybin-assisted therapy for TRD follows a similar, albeit distinct, architecture. COMPASS Pathways' COMP360 program involves a single, high-dose psilocybin session, preceded by preparatory meetings and followed by integration therapy [9]. The psilocybin induces a non-ordinary state of consciousness, often described as mystical or profoundly introspective, which can lead to rapid and sustained antidepressant effects. Researchers believe psilocybin works by increasing neural connectivity, "resetting" rigid thought patterns, and fostering new perspectives. Think of it as defragmenting a hard drive, but for the brain.
The "technology" extends far beyond the chemical compound. It encompasses:
The investment implications here are not just in the companies developing compounds. They extend to the entire ecosystem that must be built around them. This includes real estate for clinics, educational institutions for therapist training, and software developers for digital infrastructure. The molecules are merely the keys; the infrastructure is the entire kingdom that needs to be constructed.
Key Takeaway: The "technology" of psychedelic-assisted therapy is a holistic system comprising specialized compounds, meticulously designed protocols, purpose-built clinics, highly trained therapists, and integrated digital platforms.
The imminent FDA approvals for MDMA and psilocybin are not just medical milestones; they are economic earthquakes. They are poised to reshape a significant portion of the mental healthcare market. This isn't merely about shifting market share within existing categories; it's about creating an entirely new economic continent. This continent is driven by therapies that offer unprecedented efficacy for some of the most intractable mental health conditions. The implications for investors, healthcare providers, and the broader economy are profound.
First, consider the sheer scale of the unmet need. As noted, PTSD affects 13 million Americans, and TRD impacts millions more who have failed to respond to multiple conventional antidepressants [1, 2]. These conditions carry enormous societal costs. This includes lost productivity, disability benefits, and increased healthcare utilization for co-occurring physical ailments. The economic burden of depression alone is estimated at $326 billion annually in the U.S., with a significant portion attributable to TRD [10]. If psychedelic-assisted therapies can offer durable remission or significant improvement for even a fraction of these patients, the economic value generated will be staggering.
The addressable market size for these therapies is vast. Analysts project the MDMA-assisted therapy market for PTSD could reach $3 billion to $10 billion annually within five years of approval [4]. For psilocybin-assisted therapy targeting TRD and MDD, the market could be even larger, potentially $5 billion to $20 billion annually [4]. These figures are conservative, as they often don't fully account for potential future indications (e.g., eating disorders, addiction, end-of-life distress) or the global market potential. The global alternative medicine market, including these emerging therapies, is already projected to exceed $400 billion by 2028, growing at a CAGR of over 15% [11]. Psychedelic therapeutics are poised to be a significant driver of this growth, with some segments showing even higher trajectories.
The ripple effects will extend across multiple sectors:
This isn't just a niche market for "alternative" treatments; it's a mainstream medical intervention. It has the potential to profoundly alter the landscape of mental health. The economic incentives are aligning with the humanitarian imperative, creating fertile ground for innovation and investment.
The psychedelic renaissance is being built by a diverse cast of characters. From non-profit pioneers to publicly traded biotech firms, each carves out their niche in this burgeoning ecosystem. Understanding who's doing what is crucial for discerning where the investment opportunities lie.
Leading the charge for MDMA-assisted therapy for PTSD is the MAPS Public Benefit Corporation (MAPS PBC). While a non-profit, its groundbreaking clinical trials have effectively de-risked the regulatory pathway for MDMA. Their success paves the way for commercialization, likely through partnerships or licensing agreements with pharmaceutical companies, though MAPS PBC itself aims to ensure broad access and affordability [12]. Their influence extends beyond MDMA, setting a precedent for other psychedelic therapies.
In the psilocybin space, COMPASS Pathways (CMPS) stands out as the clear commercial leader. They are developing COMP360, a proprietary psilocybin formulation for TRD. Their strategy focuses on securing intellectual property around their specific formulation and therapeutic protocol, creating a defensible position in a market where the core molecule is not patentable [6]. COMPASS Pathways is building a comprehensive ecosystem, including therapist training and clinic development partnerships, positioning itself as an end-to-end solution provider.
Other notable players in the drug development arena include:
Beyond the drug developers, the infrastructure builders are emerging. Companies like Field Trip Health & Wellness Ltd. (FTRP) (though recently delisted and undergoing restructuring, their model was influential) and Numinus Wellness Inc. (NUMI) are pioneering the development and operation of specialized psychedelic therapy clinics [16, 17]. These companies are building the physical spaces and operational models necessary to deliver these complex therapies, often integrating digital platforms for patient management and therapist support. This segment is highly fragmented but critical for market expansion.
The competitive landscape is a dynamic interplay between first-movers, innovators focusing on novel compounds, and infrastructure providers. While MAPS PBC has a significant first-mover advantage for MDMA, the commercialization and scaling will require substantial capital and operational expertise. COMPASS Pathways is building a robust, integrated model for psilocybin. The challenge for all players will be to navigate regulatory complexities, scale therapist training, and ensure equitable access while building profitable businesses.
| Company/Nation | Ticker/Currency | Key Sector | Market Cap | Signal |
|---|---|---|---|---|
| COMPASS Pathways | CMPS | Psilocybin (TRD) | $450M | BULLISH |
| MindMed | MNMD | LSD, Novel Psychedelics | $250M | WATCH |
| Cybin Inc. | CYBN | Psilocybin Analogs | $120M | WATCH |
| Atai Life Sciences | ATAI | Psychedelic Pipeline | $300M | WATCH |
| Numinus Wellness Inc. | NUMI | Clinic Operations | $30M | WATCH |
The investment thesis for psychedelic-assisted therapy is not merely speculative; it's grounded in compelling clinical data, a vast unmet medical need, and the imminent regulatory catalysts of FDA approvals. This isn't a "get rich quick" scheme, but rather a long-term play on a transformative shift in mental healthcare. This is akin to the early days of biotechnology or personalized medicine. The opportunity is multi-faceted, spanning drug development, therapy delivery, and enabling technologies.
The bull case rests on several pillars. First, the efficacy data is exceptional. For PTSD and TRD, these therapies demonstrate remission rates and sustained improvements far exceeding conventional treatments. This translates directly into patient demand and, crucially, a strong value proposition for insurance payers. Second, the regulatory pathway is de-risked. Breakthrough Therapy Designations and successful Phase 3 trials have significantly reduced the uncertainty surrounding FDA approval. Third, the market size is enormous. The combined addressable market for PTSD and TRD alone represents tens of millions of patients and tens of billions of dollars in potential annual revenue. Finally, the infrastructure build-out creates multiple points of entry for investors beyond just drug development, including clinic networks, digital platforms, and therapist training.
However, a bear case must also be considered. The primary risk lies in the complexity of delivery. These are not simple take-home pills; they require intensive, supervised therapy sessions, making them expensive and difficult to scale. Regulatory bodies beyond the FDA (e.g., state medical boards, DEA scheduling) could introduce hurdles. Public perception, while improving, could still swing negatively. Reimbursement from insurance companies will be critical, and securing favorable coverage could be a protracted battle. Furthermore, the capital intensity of building out clinics and training a new workforce is significant, potentially leading to slower-than-anticipated profitability. Competition, especially from novel compounds with better intellectual property protection or more convenient delivery methods, could also erode market share.
Our conviction level remains HIGH on the long-term potential of this sector. This is coupled with a nuanced understanding of the near-term operational challenges. The fundamental scientific and medical breakthroughs are undeniable. The investment opportunities lie in identifying companies that can effectively navigate the complex interplay of drug development, regulatory compliance, and scalable therapy delivery.
Specific investment opportunities include:
The investment landscape is dynamic. However, the foundational elements for a new era of mental health treatment are firmly in place.
LONG COMPASS Pathways (CMPS) — Leading the commercialization of psilocybin for TRD with strong IP and an integrated strategy. WATCH MindMed (MNMD) — Diverse pipeline of novel psychedelic-inspired compounds with significant long-term potential if clinical milestones are met. WATCH Numinus Wellness Inc. (NUMI) — Early mover in clinic operations, critical for scaling therapy delivery, but faces capital intensity and competition.
While the promise of psychedelic-assisted therapy is immense, the path to widespread adoption and profitability is not without its formidable challenges and risks. This isn't a simple pharmaceutical market; it's a complex ecosystem requiring careful navigation. Investors must understand these potential pitfalls to make informed decisions.
The most significant challenge lies in scaling therapy delivery. Unlike traditional pills, psychedelic-assisted therapy is a high-touch, labor-intensive process. Each patient requires multiple hours of direct therapist interaction, before, during, and after the psychedelic session. This necessitates a massive expansion of the trained therapist workforce, which currently numbers in the low thousands globally for psychedelic-specific training [18]. Training new therapists is time-consuming and expensive, creating a significant bottleneck. If the supply of trained professionals cannot meet demand, patient access will be limited, and market growth will be stifled.
Regulatory hurdles extend beyond initial FDA approval. The Drug Enforcement Administration (DEA) will need to reschedule MDMA and psilocybin from Schedule I (no accepted medical use) to a more appropriate category (likely Schedule III or IV) to allow for prescription and medical use [19]. This process, while expected, is not guaranteed to be seamless and could introduce delays or restrictions. Additionally, individual states will need to establish their own regulatory frameworks for clinic licensing, therapist certification, and patient access, leading to a patchwork of regulations that could complicate national scaling efforts.
Public perception and stigma remain a lingering risk. Despite growing scientific acceptance, the historical association of psychedelics with recreational drug use could still deter some patients, healthcare providers, and policymakers. While advocacy efforts work to destigmatize these compounds, a single high-profile adverse event or misuse case could quickly erode public trust and invite stricter regulations. This industry operates under a microscope, and maintaining a pristine safety record is paramount.
From a commercial perspective, reimbursement from insurance companies is a critical, yet uncertain, factor. The high cost of these intensive therapies (potentially $10,000-$15,000 per course of treatment) will require robust data demonstrating long-term cost-effectiveness to convince payers [20]. While the potential for durable remission offers significant long-term savings by reducing chronic care, the upfront investment is substantial. Negotiations with insurers will be complex and time-consuming. Without broad insurance coverage, these therapies risk becoming accessible only to the wealthy, limiting their market penetration.
Finally, the intellectual property landscape is intricate. While companies like COMPASS Pathways have secured patents on specific psilocybin formulations and delivery methods, the core molecules themselves are generally not patentable. This could lead to a fragmented market with numerous competitors offering slightly different formulations or protocols, potentially driving down prices and profit margins over time. The "gold rush" mentality could attract too many players, leading to market saturation and consolidation.
Key Takeaway: The primary risks involve scaling the labor-intensive therapy model, navigating complex regulatory and reimbursement landscapes, and overcoming lingering public stigma.
The emergence of psychedelic-assisted therapy presents a compelling, multi-faceted investment angle that transcends traditional pharmaceutical plays. This isn't just about identifying the next blockbuster compound; it's about investing in the foundational infrastructure of a new mental health economy. For savvy investors, this means looking beyond the molecules to the entire value chain that must be constructed.
The most direct investment opportunity lies in biotech companies developing and commercializing these therapies. COMPASS Pathways (CMPS) is a prime example, with its proprietary psilocybin formulation and a clear path to market for TRD. Investing here is a bet on their ability to secure FDA approval, navigate reimbursement, and scale their integrated model. Similarly, companies like MindMed (MNMD) and Cybin Inc. (CYBN), with their focus on novel compounds and delivery systems, offer higher-risk, higher-reward propositions, betting on future clinical success and differentiated intellectual property.
However, the "picks and shovels" approach to this new gold rush might offer more diversified and potentially less volatile returns. This involves investing in the companies building the therapy infrastructure:
Investors should also consider the broader impact on adjacent sectors. If psychedelic-assisted therapies prove highly effective, they could reduce demand for some conventional antidepressants and anxiolytics. This would simultaneously boost demand for mental health support services. The long-term implications for public health spending and workforce productivity are substantial, creating a positive feedback loop for economic growth.
For those seeking diversified exposure, a few ETFs are beginning to emerge that focus on the broader psychedelic and mental health innovation space. Many are still relatively small and concentrated. These could offer a way to gain exposure without picking individual winners in a volatile, early-stage market. However, careful due diligence on their holdings and expense ratios is essential.
Tactically, investors might consider a barbell strategy. This would involve a core allocation to established players with clear regulatory pathways (e.g., CMPS) combined with smaller, speculative positions in innovative drug developers or clinic operators. The key is to recognize that this is a long-term growth story, demanding patience and a deep understanding of the evolving regulatory, clinical, and commercial terrain.
The trajectory for psychedelic-assisted therapy is clear: from fringe science to mainstream medicine, driven by undeniable efficacy and a pressing global need. The imminent FDA approvals of MDMA and psilocybin will not just introduce new compounds; they will ignite a multi-billion dollar infrastructure build-out, fundamentally re-wiring how we approach mental health treatment. This is a generational opportunity to invest in a sector poised for transformative growth, not just in financial terms, but in human well-being.
The next 2-5 years will be characterized by a frantic race to build out the necessary ecosystem. We will see a rapid expansion of specialized clinics, a surge in therapist training programs, and the maturation of digital platforms designed to support these complex therapies. Early movers who can effectively scale their operations, secure favorable reimbursement, and maintain impeccable safety records will capture significant market share. The long-term vision is a world where debilitating mental health conditions are no longer a life sentence, but treatable conditions with high rates of remission.
LONG COMPASS Pathways (CMPS) — The most advanced and commercially focused player in the psilocybin space, poised for FDA approval and market leadership. WATCH MindMed (MNMD) — A compelling pipeline of novel compounds that could unlock future indications and patentable assets, offering significant upside. WATCH Numinus Wellness Inc. (NUMI) — A key player in developing and operating the physical infrastructure for therapy delivery, critical for market expansion.
Are we finally ready to unlock the mind's full potential, and invest in the architects of its new frontier?
The impending FDA approval of MDMA and psilocybin for therapeutic use isn't just a regulatory nod; it's a seismic shift, promising to unlock a multi-billion dollar market and rewrite the playbook for mental health treatment. This isn't about recreational use; it's about a meticulously structured, medically supervised infrastructure build-out that will demand novel approaches to drug development, patient care, and even real estate. The implications are profound, creating clear winners and potential losers in an industry ripe for disruption. Investors, buckle up; the future of mental health is about to get a whole lot more interesting, and perhaps, a little trippy.
When the psychedelic tide rolls in, COMPASS Pathways (CMPS), with its NASDAQ listing and a current market capitalization hovering around $500 million (as of late 2023), is positioned to ride the crest of the wave. Why? Because they're not just dabbling; they're building the infrastructure for psilocybin-assisted therapy for treatment-resistant depression (TRD) with an almost obsessive focus. Their competitive advantage is multi-faceted: proprietary synthetic psilocybin (COMP360), a robust intellectual property portfolio, and, crucially, a comprehensive therapist training program. This isn't just a drug; it's a system. While others are chasing various psychedelic molecules, CMPS has honed in on a single, high-impact indication with a clear regulatory pathway. Their Phase 3 program is well underway, with top-line data from their first pivotal trial expected mid-2024, placing them squarely in line for potential FDA approval soon after MAPS PBC's MDMA. Financially, CMPS is a clinical-stage biotech, meaning profitability is a future state, but their cash runway is substantial, backed by strategic investors. Their investment thesis is straightforward: they are the most advanced, well-funded, and strategically focused pure-play in the psilocybin space, targeting a massive unmet medical need. If COMP360 secures approval, CMPS will be the first-mover in a potentially multi-billion dollar market for TRD, establishing a gold standard for care. However, risks abound: clinical trial failures, regulatory hurdles, potential competition from generic psilocybin post-patent expiry, and the sheer logistical challenge of scaling a complex therapy. Investors must weigh the significant upside against the inherent volatility and execution risk of a pioneering biotech.
While the psychedelic renaissance offers hope, it casts a long shadow over incumbent players in the mental health space, particularly those with less differentiated or older-generation assets. Enter Acadia Pharmaceuticals (ACAD), a company with a market capitalization of approximately $3.5 billion, primarily known for Nuplazid (pimavanserin), approved for Parkinson's Disease Psychosis (PDP) and recently for dementia-related psychosis (DRP). While not a direct antidepressant, ACAD's core business relies on addressing psychosis and agitation, conditions that often co-occur with or are exacerbated by severe depression and other mental health disorders. The threat to ACAD isn't direct competition for Nuplazid's specific indications, but rather a broader shift in the mental health treatment paradigm. As psychedelic-assisted therapies like psilocybin for TRD gain traction, they offer a potentially more profound, longer-lasting, and fundamentally different approach to mental illness than daily oral medications. If patients achieve sustained remission from TRD, for instance, the downstream demand for palliative or symptomatic treatments for associated conditions could diminish. ACAD's vulnerability lies in its reliance on a traditional pharmaceutical model, which may struggle to compete with the holistic, intensive, and potentially curative nature of psychedelic therapy. The investment thesis for caution is that ACAD, while profitable, operates in a segment that could see its market share and patient pool gradually eroded or, at the very least, its growth trajectory blunted by the emergence of truly transformative therapies. Potential catalysts for decline include widespread adoption of psychedelic therapies, favorable reimbursement for these new modalities, and a growing preference among patients and clinicians for treatments that address root causes rather than just symptoms. While ACAD has diversified into Rett Syndrome with Daybue, its legacy mental health portfolio remains exposed to this evolving landscape, making it a company that investors should watch with a skeptical eye as the psychedelic era dawns.
May your portfolios be as green as the energy we just discussed. Until next time, keep your stops tight and your research deep.
— The Vetta Research Team
[1] World Health Organization, "Depression," 2023, https://www.who.int/news-room/fact-sheets/detail/depression [2] National Center for PTSD, "How Common is PTSD in Adults?," U.S. Department of Veterans Affairs, 2022, https://www.ptsd.va.gov/understand/common/common_adults.asp [3] U.S. Food & Drug Administration, "Breakthrough Therapy Designation," 2018, https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/breakthrough-therapy [4] Data Bridge Market Research, "Psychedelic Drugs Market - Industry Trends and Forecast to 2028," 2021, https://www.databridgemarketresearch.com/reports/global-psychedelic-drugs-market (Note: Specific $10-100B range is an aggregated analyst estimate from various sources, including internal Vetta analysis, based on compound annual growth rates and expanded indications.) [5] Multidisciplinary Association for Psychedelic Studies (MAPS), "MDMA-Assisted Therapy for PTSD," 2023, https://maps.org/mdma/ [6] COMPASS Pathways, "COMP360 Psilocybin Therapy," 2023, https://www.compasspathways.com/our-approach/comp360-psilocybin-therapy/ [7] Usona Institute, "About Psilocybin Research," 2023, https://usonainstitute.org/about-psilocybin-research/ [8] Mithoefer, M. C., et al., "MDMA-assisted psychotherapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study," Nature Medicine, 2021, https://www.nature.com/articles/s41591-021-01336-3 [9] Goodwin, G. M., et al., "Single-dose psilocybin for a treatment-resistant episode of major depression," New England Journal of Medicine, 2021, https://www.nejm.org/doi/full/10.1056/NEJMoa20329 psilocybin for TRD [10] Greenberg, P. E., et al., "The economic burden of adults with major depressive disorder in the United States (2005 and 2010)," Journal of Clinical Psychiatry, 2015, https://pubmed.ncbi.nlm.nih.gov/25654303/ [11] Grand View Research, "Alternative Medicine Market Size, Share & Trends Analysis Report," 2021, https://www.grandviewresearch.com/industry-analysis/alternative-medicine-market [12] MAPS Public Benefit Corporation, "About Us," 2023, https://mapsbpc.com/about-us/ [13] MindMed, "Our Pipeline," 2023, https://mindmed.com/our-pipeline/ [14] Cybin Inc., "Our Pipeline," 2023, https://www.cybin.com/pipeline/ [15] Atai Life Sciences, "Our Pipeline," 2023, https://www.atai.life/pipeline/ [16] Field Trip Health & Wellness Ltd., "Company Information," 2023, (Note: Company undergoing restructuring, information based on prior public filings.) [17] Numinus Wellness Inc., "Our Clinics," 2023, https://numinus.com/our-clinics/ [18] American Psychedelic Practitioners Association, "Training Programs," 2023, https://www.appainfo.org/training-programs (Note: General estimate based on available programs and certified graduates.) [19] Drug Enforcement Administration, "Drug Scheduling," 2023, https://www.dea.gov/drug-information/drug-scheduling [20] The New York Times, "The Cost of Psychedelic Therapy," 2022, https://www.nytimes.com/2022/08/04/well/mind/psychedelic-therapy-cost.html
All sources were verified at the time of publication. For specific citations, contact [email protected].
Disclaimer: The information provided in this article is for educational and informational purposes only and does not constitute investment advice, a solicitation, or a recommendation to buy or sell any security. Vetta Investments does not guarantee the accuracy, completeness, or timeliness of any information presented. Past performance is not indicative of future results. All investments involve risk, including the possible loss of principal. Readers should conduct their own due diligence and consult a qualified financial advisor before making any investment decisions. Vetta Investments may hold positions in securities mentioned in this article.